Acquiring Exclusive Distribution Rights for Desloratadine
First written in FY2017-Q1. 5 of 13 entries say "Restated". Latest entry: FY2022-Q1.
No other company in this theme has enough history to compare yet.
- FY2022-Q1RestatedAnnual report
「The core products Beova, a treatment for overactive bladder, and Desalex, an allergy treatment, grew, but」
Continued reporting of growth in Desalex as a core product following the resumption of supply. - FY2021-Q3RestatedAnnual report
「The core products Beova, a treatment for overactive bladder, and Desalex, an allergy treatment, grew,」
Continued reporting of growth in Desalex as a core product following the resumption of supply. - FY2021-Q2RestatedAnnual report
「The core products Beova, a treatment for overactive bladder, and Desalex, an allergy treatment, grew, but」
Continued reporting of growth in sales of Desalex following the resumption of supply. - FY2021-Q1RestatedAnnual report
「The core products Beova, a treatment for overactive bladder, and Desalex, an allergy treatment, grew, but」
Growth in Desalex sales following the resumption of supply is reported as a sales result. - FY2020-Q3MitigatedAnnual report
「On the other hand, the impact of the supply suspension of Desalex, a sustained selective H1 receptor antagonist and allergy treatment, whose supply resumed in November of the same year」
While supply of Desalex, which had been suspended following the voluntary recall, resumed in November 2019, the impact of the supply suspension continued to affect sales. - FY2020-Q2RestatedAnnual report
「On the other hand, the impact of the temporary supply suspension of Desalex, a sustained selective H1 receptor antagonist and allergy treatment」
The temporary supply suspension of Desalex, which was sold under exclusive rights, continued to affect sales. - FY2019SoftenedAnnual report
「Supply of Desalex, a sustained selective H1 receptor antagonist and allergy treatment, was temporarily suspended from 7 January 2019 after MSD K.K., the marketing authorization holder, decided to conduct a voluntary product recall.」
For Desalex, which was sold under exclusive rights, the voluntary recall led to a temporary suspension of product supply, weakening the basis for continued sales. - FY2018Cited as achievedAnnual report
「For Desalex, an allergy treatment for which long-term prescriptions became possible in December 2017 following the lifting of the prescription-duration restriction for new drugs, the Company focused on market penetration and expanding prescription volume, with the result that」
The lifting of the prescription-duration restriction and market penetration following the launch and approval of the desloratadine product are cited as results. - FY2018-Q3AdvancedAnnual report
「For Desalex, an allergy treatment for which long-term prescriptions became possible in December 2017 following the lifting of the prescription-duration restriction for new drugs, the Company focused on market penetration and expanding prescriptions, with the result that」
For the desloratadine product for which exclusive sales rights were acquired, the prescription-duration restriction was lifted after launch, and the product moved to the stage of achieving market penetration and expanding prescriptions. - FY2017Cited as achievedAnnual report
「In the current fiscal year, Desalex Tablets 5mg, an allergy treatment, was newly launched in November 2016, and」
The launch of the desloratadine product following the acquisition of exclusive sales rights and approval is cited as a result. - FY2017-Q3AdvancedAnnual report
「As a new product, Desalex Tablets 5mg, an allergy treatment, was newly launched in November 2016.」
For the desloratadine product, Desalex was launched following the acquisition of exclusive sales rights and marketing approval. - FY2017-Q2AdvancedAnnual report
「For Desalex Tablets 5mg, an allergy treatment for which Kyorin Pharmaceutical Co., Ltd. held exclusive sales rights in Japan, MSD K.K., which had applied for marketing approval for the drug, obtained marketing approval in September 2016.」
Following the acquisition of exclusive sales rights, concrete progress was made with the approval of Desalex for manufacture and marketing. - FY2017-Q1First statedAnnual report
「In May 2016, the agreement for the allergy treatment desloratadine was amended, and KYORIN Pharmaceutical Co.,Ltd. acquired exclusive distribution rights.」
The agreement was changed from domestic co-distribution rights to exclusive distribution rights.